ENTEROSTATIN AS THERAPEUTIC AGENT FOR HYPOGLYCEMIA

摘要

It has been discovered that enterostatin injections into mice caused an increase in blood glucose levels within 15 minutes of injection, and the glucose levels remained high for up to an hour after injection. In addition, mice injected with enterostatin showed less of an initial decrease in blood glucose following an insulin injection. Enterostatin was also shown to decrease AMPK activity in both mice and human tissues, which is additional support that glucose production is increased after enterostatin injection. This ability to enhance glucose production indicates that enterostatin could be used to treat hypoglycemia.